Bli medlem
Bli medlem

Du är här

2016-09-02

Orion Oyj: Orion Corporation and Menarini Group collaborate on budesonide-formoterol Easyhaler® combination product for asthma and COPD

Press release 2 September 2016 at 1.00 p.m. EEST

Orion Corporation announced today that it has entered into a collaboration
agreement with Menarini Group, for the co-marketing of budesonide-formoterol
Easyhaler
®combination product in Germany, Italy, Spain, and Portugal. In addition, the
parties have agreed on an exclusive license and distribution arrangement in
France and Turkey. Both companies will market budesonide-formoterol Easyhaler
®for the treatment of asthma and COPD under their own brands accompanied by
the
Easyhaler
®umbrella brand, as applicable.

Respiratory is one of the key strategic areas for Menarini. The collaboration
with Menarini reinforces Orion's presence throughout Europe and is in line
with Orion's strategy to strengthen its marketing position in Europe and the
sales coverage through partnerships. The co-marketing area - in which both
companies present their own product brands under the Easyhaler®umbrella brand
- coversGermany
,Italy
,Spain
, andPortugal
. Orion will retain exclusive marketing rights for the Nordic countries, U.K.
and Eastern Europe where the company is currently promoting
Easyhaler®products. Orion will manufacture the budesonide-formoterol
Easyhaler®product covered by the agreement.

Markku Huhta-Koivisto
, Senior Vice President of Orion's Proprietary Products division, commented:

"I am excited about the collaboration between Orion and Menarini and look
forward to having such
a strong partner focusing on respiratory therapy area. The collaboration
accelerates the good momentum we have for Easyhaler products in Europe and
strengthens Orion's strategic objective to become a stronger player in the
field of respiratory medication."

Dr. Pio Mei
, General Manager of The Menarini Group, commented:

"We are most satisfied with the agreement and the co-operation between the
Menarini Group and Orion. Menarini's mission is to make high quality
products available to patients all over the world, offering an increasingly
wider range of products for the treatment of respiratory diseases."

About budesonide-formoterol Easyhaler
®

Budesonide-formoterol Easyhaler®is an inhaled combination product indicated
for asthma and chronic obstructive pulmonary disease (COPD). In this
formulation, budesonide acts as an anti-inflammatory agent and formoterol
acts as a long-acting bronchodilator. The product is available under the
brand name Bufomix Easyhaler®in most of the European countries, with
following exceptions: Fobuler®in Italy and Bufoler Easyhaler®in the
Netherlands.

Orion's Easyhaler®is an in-house developed dry-powder inhaler. Orion has
developed Easyhaler-adapted dry powder formulations of several well-known
generic active substances (salbutamol, beclometasone, budesonide, formoterol)
used in the treatment of asthma and COPD. At the moment under development is
new combined formulation of fluticasone-salmeterol for the treatment of
asthma and COPD.

About Menarini Group

The Menarini Group is the number one Italian pharmaceutical company in the
world, 19th in Europe out of 5,541 companies, and 39th company in the world
out of 21,317 companies, with a turnover of over 3.3 billion Euro and more
than 16,000 employees. The Menarini Group has always pursued two strategic
objectives: Research and Internationalisation. Menarini is present in the
most important therapeutic areas including cardiovascular products,
gastroenterology products, oncology, andrology, antibiotics/respiratory
products, drugs used in diabetology, anti-inflammatory agents/analgesics.
With a consolidated presence throughout Europe and in the major countries of
Asia, Africa, Central and South America, its own 6 Research Centres and 15
Production sites, Menarini products are available to patients in more than
100 countries worldwide. For more information about Menarini Group, please
visit: http://www.menarini.com/

Contact person:

Markku Huhta-Koivisto,
Senior Vice President, Proprietary Products, Orion Corporation
markku.huhta-koivisto@orionpharma.com

+358 10 426 3540

Publisher
Orion Corporation

Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en

Twitter: @OrionPharma&@OrionCorpIR

Orion is a globally operating Finnish company developing pharmaceuticals and
diagnostic tests - a builder of well-being. Orion develops, manufactures and
markets human and veterinary pharmaceuticals, active pharmaceutical
ingredients and diagnostic tests. The company is continuously developing new
drugs and treatment methods. The core therapy areas of Orion's pharmaceutical
R&D are central nervous system (CNS) disorders, oncology and respiratory for
which Orion develops inhaled Easyhaler® pulmonary drugs.

Orion's net sales in 2015 amounted to EUR 1,016 million and the Company had
about 3,400 employees. Orion's A and B shares are listed on Nasdaq Helsinki.

Press release_BF EH_menarini_en
http://hugin.info/3079/R/2039323/760126.pdf

---------------------------------------

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Orion Oyj via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.